Table 2.

Adverse events, according to dose level, associated with treatment with vemurafenib in combination with irinotecan and cetuximab

TotalGrade 1Grade 2Grade 3Grade 4Grades 1–2Grades 3–4Total%
Alopecia31141526
Anemia7621321579
Anorexia731001053
Arthralgia51262842
Blurry vision11015
Constipation440421
Cramping11015
Diarrhea6551151684
Dry heaves11015
Dry mouth11015
Dyspnea4150526
Epistaxis11015
Fatigue9621521789
Fever11015
Flushing11015
GERD11015
HFS220211
HTN11015
Inc bilirubin11015
Inc LFT11015
Infection11015
Leukopenia233154947
Low albumin11015
Low K11015
Low Mg220211
Mucositis4150526
Myalgia921101158
Nausea11311411579
Neuropathy4260632
Proteinuria11015
Pruritis11015
Rash12111311474
Taste change11015
Vomiting5160632
Weight loss1120211
  • Abbreviations: Inc LFT, increased liver function tests; GERD, gastroesophageal reflux disease; HFS, hand-foot syndrome; HTN, hypertension; Low K, low potassium; Low Mg, low magnesium.